Published in Clin Exp Immunol on February 01, 2005
n-3 polyunsaturated fatty acids suppress the localization and activation of signaling proteins at the immunological synapse in murine CD4+ T cells by affecting lipid raft formation. J Immunol (2008) 1.55
Regulatory activity of polyunsaturated fatty acids in T-cell signaling. Prog Lipid Res (2010) 1.39
Th17 cell accumulation is decreased during chronic experimental colitis by (n-3) PUFA in Fat-1 mice. J Nutr (2011) 1.08
Incorporation of a dietary omega 3 fatty acid impairs murine macrophage responses to Mycobacterium tuberculosis. PLoS One (2010) 0.86
Dietary fish oil and DHA down-regulate antigen-activated CD4+ T-cells while promoting the formation of liquid-ordered mesodomains. Br J Nutr (2013) 0.82
n-3 PUFAs reduce T-helper 17 cell differentiation by decreasing responsiveness to interleukin-6 in isolated mouse splenic CD4⁺ T cells. J Nutr (2014) 0.77
Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 22.57
Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med (1991) 16.81
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med (1989) 15.15
IL-10 inhibits cytokine production by activated macrophages. J Immunol (1991) 13.13
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med (1991) 8.78
CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 7.15
Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A (1992) 6.37
Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science (1992) 5.36
Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol (1993) 4.88
Interleukin 10, a novel B cell stimulatory factor: unresponsiveness of X chromosome-linked immunodeficiency B cells. J Exp Med (1990) 4.30
Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest (1995) 3.43
Molecular basis of T cell inactivation by CTLA-4. Science (1998) 3.00
High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med (1994) 2.70
The orphan receptor CRF2-4 is an essential subunit of the interleukin 10 receptor. J Exp Med (1998) 2.55
IL-10: a novel cytotoxic T cell differentiation factor. J Immunol (1991) 2.32
Interferon-gamma: biology and role in pathogenesis. Adv Immunol (1996) 2.08
Identification and functional characterization of a second chain of the interleukin-10 receptor complex. EMBO J (1997) 2.03
A receptor for interleukin 10 is related to interferon receptors. Proc Natl Acad Sci U S A (1993) 1.91
Expression cloning and characterization of a human IL-10 receptor. J Immunol (1994) 1.89
Mechanisms of interleukin-10-mediated immune suppression. Immunology (2001) 1.70
Dietary (n-3) polyunsaturated fatty acids remodel mouse T-cell lipid rafts. J Nutr (2003) 1.56
Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma. Hepatology (1992) 1.30
IL-10 directly acts on T cells by specifically altering the CD28 co-stimulation pathway. Eur J Immunol (2000) 1.30
IFN-gamma induces IL-12 mRNA expression by a murine macrophage cell line, J774. Biochem Biophys Res Commun (1994) 1.25
Reprogramming of IL-10 activity and signaling by IFN-gamma. J Immunol (2003) 1.24
Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol (1997) 1.21
Differential IL-10R1 expression plays a critical role in IL-10-mediated immune regulation. J Immunol (2001) 1.18
Comparison of the suppressive effects of interleukin-10 and interleukin-4 on synovial fluid macrophages and blood monocytes from patients with inflammatory arthritis. Immunology (1995) 1.12
IFN-gamma priming of monocytes enhances LPS-induced TNF production by augmenting both transcription and MRNA stability. Cytokine (1995) 1.07
Dietary n-3 polyunsaturated fatty acids promote activation-induced cell death in Th1-polarized murine CD4+ T-cells. J Lipid Res (2004) 1.04
Dietary n-3 polyunsaturated fatty acids modulate purified murine T-cell subset activation. Clin Exp Immunol (2001) 1.01
Effects of purified dietary n-3 ethyl esters on murine T lymphocyte function. J Immunol (1993) 1.00
Interferon-gamma induces Ice gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem Biophys Res Commun (1996) 0.99
Docosahexaenoic acid suppresses function of the CD28 costimulatory membrane receptor in primary murine and Jurkat T cells. J Nutr (2001) 0.96
The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts. J Biol Chem (2002) 0.93
IL-10 receptor dysfunction in macrophages during chronic inflammation. J Leukoc Biol (2001) 0.90
Paradoxical antidiabetogenic effect of gamma-interferon in DP-BB rats. Diabetes (1998) 0.86
IFN-gamma inhibits inflammatory cell recruitment and the evolution of bacterial cell wall-induced arthritis. J Immunol (1991) 0.85
Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon-gamma and bacterial lipopolysaccharide. Trans Assoc Am Physicians (1993) 0.81
Why are doctors so unhappy? There are probably many causes, some of them deep. BMJ (2001) 22.59
Evidence based medicine. BMJ (1995) 21.24
What clinical information do doctors need? BMJ (1996) 16.23
Three-dimensional structure of myosin subfragment-1: a molecular motor. Science (1993) 14.90
Informed consent: the intricacies. BMJ (1997) 13.97
An ethical code for everybody in health care. BMJ (1998) 9.13
All changed, changed utterly. British medicine will be transformed by the Bristol case. BMJ (1998) 9.08
Growing pressure on BMJ's obituaries. BMJ (1995) 8.92
Authorship: time for a paradigm shift? BMJ (1997) 8.90
A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med (1991) 8.65
The failings of NICE. BMJ (2000) 8.50
The future of medicine. BMJ (1994) 8.14
A good death. An important aim for health services and for us all. BMJ (2000) 8.03
Using evidence to inform health policy: case study. BMJ (2001) 7.99
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Time to face up to research misconduct. BMJ (1996) 7.66
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature (2000) 7.66
Beyond conflict of interest. Transparency is the key. BMJ (1998) 7.63
Meeting the information needs of health workers in developing countries. BMJ (1997) 6.31
Medicine's core values. BMJ (1994) 5.93
Revel in electronic and paper media. BMJ (2000) 5.82
The GMC on performance. BMJ (1992) 5.57
Informed consent: edging forwards (and backwards) BMJ (1998) 5.52
PubMed Central: creating an Aladdin's cave of ideas. BMJ (2001) 5.49
Does Britain need an academy of medicine? BMJ (1996) 5.47
Effect of open peer review on quality of reviews and on reviewers' recommendations: a randomised trial. BMJ (1999) 5.45
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
Rationing: the search for sunlight. BMJ (1992) 5.26
Publishing information about patients. BMJ (1995) 5.19
The future of healthcare systems. BMJ (1997) 5.14
Prejudice against doctors and students from ethnic minorities. Br Med J (Clin Res Ed) (1987) 5.12
The war on drugs. BMJ (1996) 5.11
Global information flow. BMJ (2000) 5.09
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
What makes a good reviewer and a good review for a general medical journal? JAMA (1998) 5.01
Where is the wisdom...? BMJ (1991) 4.85
Medicine and the marginalised. They deserve the best, not the poorest, care. BMJ (2000) 4.80
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
X-ray structures of the myosin motor domain of Dictyostelium discoideum complexed with MgADP.BeFx and MgADP.AlF4-. Biochemistry (1995) 4.64
Time to register randomised trials. The case is now unanswerable. BMJ (1999) 4.55
PFI: perfidious financial idiocy. A "free lunch" that could destroy the NHS. BMJ (1999) 4.54
Moving beyond journals: the future arrives with a crash. BMJ (1999) 4.49
Rationing: the debate we have to have. BMJ (1995) 4.47
Time to redefine authorship. BMJ (1996) 4.39
Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol. J Virol (1987) 4.37
Animal research: the need for a middle ground. BMJ (2001) 4.34
Conflict of interest and the BMJ. BMJ (1994) 4.34
Prison medicine: beginning again. BMJ (1992) 4.29
Measuring the social impact of research. BMJ (2001) 4.17
The case for structuring the discussion of scientific papers. BMJ (1999) 4.16
Peer review: reform or revolution? BMJ (1997) 4.13
Profile of the GMC: The day of judgment comes closer. BMJ (1989) 4.10
Managing the clinical performance of doctors. A coherent response to an intractable problem. BMJ (1999) 4.08
Effect of blinding and unmasking on the quality of peer review: a randomized trial. JAMA (1998) 4.03
The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis (2004) 3.94
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol (2001) 3.92
Tumorigenesis by mouse mammary tumor virus: evidence for a common region for provirus integration in mammary tumors. Cell (1983) 3.89
Protein kinase activity associated with polyoma virus middle T antigen in vitro. Cell (1979) 3.78
Profile of the GMC. 1978 and all that. BMJ (1989) 3.76
"Taken from this place and hanged by the neck...". BMJ (1991) 3.72
The rights of patients in research. BMJ (1995) 3.68
All doctors are problem doctors. BMJ (1997) 3.67
The BMJ's website scales up. BMJ (1998) 3.67
Publishing research supported by the tobacco industry. BMJ (1996) 3.65
Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res (1994) 3.65
How best to organise acute hospital services? BMJ (2001) 3.63
Tumorigenesis by mouse mammary tumor virus: proviral activation of a cellular gene in the common integration region int-2. Cell (1984) 3.61
Netprints: the next phase in the evolution of biomedical publishing. BMJ (1999) 3.60
GMC: approaching the abyss. BMJ (2001) 3.52
The deliberate misdiagnosis of major depression in primary care. Arch Fam Med (1994) 3.46
Pleasing both authors and readers. A combination of short print articles and longer electronic ones may help us do this. BMJ (1999) 3.44
New government, same narrow vision. BMJ (1998) 3.40
Don't treat shackled patients. BMJ (1997) 3.40
The woolwich and erith project. Planning a community health service. Lancet (1966) 3.34
Almost no evidence exists that the internet harms health. BMJ (2001) 3.31
Characterization of different tumor antigens present in cells transformed by simian virus 40. Cell (1979) 3.26
Appendicular skeletal muscle mass: measurement by dual-photon absorptiometry. Am J Clin Nutr (1990) 3.24
The estimation of two collagens from human dermis by interrupted gel electrophoresis. Biochem Biophys Res Commun (1976) 3.22
Opening up BMJ peer review. BMJ (1999) 3.21
Doctors, unethical treatments, and turning a blind eye. BMJ (1989) 3.13
Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst (1999) 3.07
Reconfiguring acute hospital services. No easy answers, but there are principles we should follow. BMJ (1999) 3.07
Authorship is dying: long live contributorship. BMJ (1997) 3.07
Hamster health care. BMJ (2001) 3.06
Promoting research into peer review. BMJ (1994) 3.05
Rationing health care: moving the debate forward. BMJ (1996) 3.03
BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res (2000) 3.01
GMC in the dock again. BMJ (1993) 2.99
Maintaining the integrity of the scientific record. BMJ (2001) 2.98
Altered relation of two collagen types in osteogenesis imperfecta. N Engl J Med (1977) 2.93
Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science (1988) 2.93
DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry (2004) 2.91
A randomised comparison of strategies for reducing infective complications of induced abortion. Br J Obstet Gynaecol (1998) 2.86
A placental clock controlling the length of human pregnancy. Nat Med (1995) 2.86
A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract (2002) 2.86
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol (2001) 2.81
A randomized study of outpatient treatment with ceftriaxone for selected febrile children with sickle cell disease. N Engl J Med (1993) 2.80
Peering into the bowels of the MRC. I: Setting priorities. Br Med J (Clin Res Ed) (1988) 2.76
Light-chain phosphorylation controls the conformation of vertebrate non-muscle and smooth muscle myosin molecules. Nature (1983) 2.73
The Cataract National Dataset electronic multi-centre audit of 55,567 operations: variation in posterior capsule rupture rates between surgeons. Eye (Lond) (2009) 2.73